A Concise Overview of Biosensing Technologies for the Detection of Alzheimer's Disease Biomarkers

Curr Pharm Biotechnol. 2022;23(5):634-644. doi: 10.2174/2666796702666210709122407.

Abstract

Alzheimer's disease (AD) is a brain-linked pathophysiological condition with neuronal degeneration and cognition dysfunctions and other debilitations. Due to the growing prevalence of AD, there is a highly commended trend to accelerate and develop analytical technologies for easy, costeffective, and sensitive detection of AD biomarkers. Biosensors are commanding analytical devices that can conduct biological responses on transducers into measurable signals. This review focuses on up-todate developmets, contests, and tendencies regarding AD biosensing principally, with the emphasis on the exclusive possessions of nanomaterials. In the last decade, remarkable advancements have been achieved to the progression of biosensors, predominantly optical and electrochemical, for the detection of AD biomarkers. These analytical devices can assist the case finding and management of AD.

Keywords: Alzheimer’s disease; amyloid-β; apolipoprotein E; biomarkers; biosensors; nanomaterials.; tau protein.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Amyloid beta-Peptides
  • Biomarkers
  • Biosensing Techniques*
  • Cognitive Dysfunction*
  • Humans
  • Nanostructures*
  • tau Proteins

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • tau Proteins